Beam Therapeutics Inc. BEAM incurred a loss of $1.22 per share in the third quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of $1.37. The company had recorded a loss of $1.56 per ...
Wall Street expects a year-over-year increase in earnings on lower revenues when Beam Therapeutics Inc. (BEAM) reports results for the quarter ended September 2023. While this widely-known consensus ...
Shares of Beam Therapeutics (NASDAQ:BEAM) reached a 52-week high on Tuesday after the gene-editing company swung to profits in Q4, exceeding Wall Street projections as its revenue jumped thanks to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results